Cargando…
Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study
Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727250/ https://www.ncbi.nlm.nih.gov/pubmed/36505494 http://dx.doi.org/10.3389/fimmu.2022.1066916 |
_version_ | 1784844971539431424 |
---|---|
author | Abe, Nobuya Kono, Michihiro Kono, Michihito Katsuyama, Takayuki Ohmura, Kazumasa Sato, Taiki Karino, Kohei Fujieda, Yuichiro Kato, Masaru Hasebe, Rie Murakami, Masaaki Atsumi, Tatsuya |
author_facet | Abe, Nobuya Kono, Michihiro Kono, Michihito Katsuyama, Takayuki Ohmura, Kazumasa Sato, Taiki Karino, Kohei Fujieda, Yuichiro Kato, Masaru Hasebe, Rie Murakami, Masaaki Atsumi, Tatsuya |
author_sort | Abe, Nobuya |
collection | PubMed |
description | Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between the disease state and cytokine/chemokine levels, to assess disease course as prognosis and to predict regulators in patients with LVV using the blood profiles of multiple cytokines/chemokines. This retrospective analysis comprised 35 LVV patients whose blood were collected, and multiplex cytokine/chemokine analysis with 28 analytes was performed. The differences of cytokines/chemokines corresponding disease status, upstream regulator analysis, pathway analysis and cluster analysis were conducted using the cytokines/chemokines profile. Relapse-free survival rate was calculated with Kaplan-Meier analysis in the classified clusters. In the robust analysis, IL-4, CCL2/MCP-1, TNFSF13/APRIL, TNFSF13B/BAFF, CHI3L1 and VEGF-A levels were significantly changed after treatment. Untreated LVV patients demonstrated activation of NFκB-related molecules and these patients are potentially treated with JAK/STAT inhibitors, anti-TNF-α inhibitors and IL-6 inhibitors. Cluster analysis in active LVV patients revealed two clusters including one with high blood levels of IL-1β, IL-6, IL-17, IL-23 and CCL20/MIP-3. A subgroup of the LVV patients showed activated IL-17 signature with high relapse frequency, and JAK/TyK2 inhibitors and IFN-γ inhibitors were detected as potentially upstream inhibitors. Blood cytokine/chemokine profiles would be useful for prediction of relapse and potentially contributes to establish therapeutic strategy as precision medicine in LVV patients. |
format | Online Article Text |
id | pubmed-9727250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97272502022-12-08 Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study Abe, Nobuya Kono, Michihiro Kono, Michihito Katsuyama, Takayuki Ohmura, Kazumasa Sato, Taiki Karino, Kohei Fujieda, Yuichiro Kato, Masaru Hasebe, Rie Murakami, Masaaki Atsumi, Tatsuya Front Immunol Immunology Large-vessel vasculitis (LVV) is subclassified into two phenotypes; Takayasu arteritis and giant cell arteritis. Although the pathogenesis of LVV is not fully established, IL-6−IL-17 axis and IL-12−IFN-γ axis play critical roles in the disease development. We aimed to clarify the association between the disease state and cytokine/chemokine levels, to assess disease course as prognosis and to predict regulators in patients with LVV using the blood profiles of multiple cytokines/chemokines. This retrospective analysis comprised 35 LVV patients whose blood were collected, and multiplex cytokine/chemokine analysis with 28 analytes was performed. The differences of cytokines/chemokines corresponding disease status, upstream regulator analysis, pathway analysis and cluster analysis were conducted using the cytokines/chemokines profile. Relapse-free survival rate was calculated with Kaplan-Meier analysis in the classified clusters. In the robust analysis, IL-4, CCL2/MCP-1, TNFSF13/APRIL, TNFSF13B/BAFF, CHI3L1 and VEGF-A levels were significantly changed after treatment. Untreated LVV patients demonstrated activation of NFκB-related molecules and these patients are potentially treated with JAK/STAT inhibitors, anti-TNF-α inhibitors and IL-6 inhibitors. Cluster analysis in active LVV patients revealed two clusters including one with high blood levels of IL-1β, IL-6, IL-17, IL-23 and CCL20/MIP-3. A subgroup of the LVV patients showed activated IL-17 signature with high relapse frequency, and JAK/TyK2 inhibitors and IFN-γ inhibitors were detected as potentially upstream inhibitors. Blood cytokine/chemokine profiles would be useful for prediction of relapse and potentially contributes to establish therapeutic strategy as precision medicine in LVV patients. Frontiers Media S.A. 2022-11-23 /pmc/articles/PMC9727250/ /pubmed/36505494 http://dx.doi.org/10.3389/fimmu.2022.1066916 Text en Copyright © 2022 Abe, Kono, Kono, Katsuyama, Ohmura, Sato, Karino, Fujieda, Kato, Hasebe, Murakami and Atsumi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Abe, Nobuya Kono, Michihiro Kono, Michihito Katsuyama, Takayuki Ohmura, Kazumasa Sato, Taiki Karino, Kohei Fujieda, Yuichiro Kato, Masaru Hasebe, Rie Murakami, Masaaki Atsumi, Tatsuya Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title | Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title_full | Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title_fullStr | Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title_full_unstemmed | Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title_short | Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: A preliminary observational study |
title_sort | cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel vasculitis: a preliminary observational study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727250/ https://www.ncbi.nlm.nih.gov/pubmed/36505494 http://dx.doi.org/10.3389/fimmu.2022.1066916 |
work_keys_str_mv | AT abenobuya cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT konomichihiro cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT konomichihito cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT katsuyamatakayuki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT ohmurakazumasa cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT satotaiki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT karinokohei cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT fujiedayuichiro cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT katomasaru cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT haseberie cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT murakamimasaaki cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy AT atsumitatsuya cytokineandchemokinemultiplexanalysisbasedexplorationforpotentialtreatmentandprognosticpredictioninlargevesselvasculitisapreliminaryobservationalstudy |